Li Jun, Lv Yu-min, Jin Zhu, Cui Rong-li
Department of Gastroenterology, Peking University Third Hospital, Beijing 100083, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2005 Aug 18;37(4):371-3.
To evaluate the long-term effectiveness of sulindac on the pathology of colorectal adenomas of familial adenomatous polyposis (FAP) patients.
FAP patients were treated with sulindac 400 mg per day. The change of colorectal polyps was assessed every 3 months in the first year. After the significant regression of colorectal polyps was achieved, sulindac was used to maintain the effects. The patients received colonoscopy examination regularly. Biopsies of remnant polyps and other lesions were obtained. The type and dysplasia grade of biopsies were evaluated and compared with baseline.
Before the study, 90.8% of adenoma biopsies were tubular, while 9.2% was tubulovillous adenoma. The dysplasia of grades I, II and III were 42.1%, 45.6% and 12.3%, respectively. After sulindac treatment, 99.8% of adenoma biopsies were tubular, while 0.2% tubulovillous adenoma. There was significant difference compared with baseline (P<0.01). The dysplasia of grades I, II and III were 55.8%, 41.8% and 2.4% respectively, which had significant difference with baseline (P<0.01). Minor flat elevation and erythema were found during the treatment, in which approximately 65% was adenoma.
Long-term use of sulindac seems to be effective in reducing dysplasia grade and tubulovillous adenoma of retained colorectal adenoma of FAP patients. Minor flat elevation and erythema may be the lesions appearing during the regression of adenoma.
评估舒林酸对家族性腺瘤性息肉病(FAP)患者大肠腺瘤病理的长期疗效。
FAP患者每日服用舒林酸400毫克。在第一年,每3个月评估一次大肠息肉的变化。在大肠息肉显著消退后,使用舒林酸维持疗效。患者定期接受结肠镜检查。获取残留息肉和其他病变的活检样本。评估活检样本的类型和发育异常分级,并与基线进行比较。
研究前,90.8%的腺瘤活检样本为管状,而9.2%为管状绒毛状腺瘤。I级、II级和III级发育异常分别为42.1%、45.6%和12.3%。舒林酸治疗后,99.8%的腺瘤活检样本为管状,而0.2%为管状绒毛状腺瘤。与基线相比有显著差异(P<0.01)。I级、II级和III级发育异常分别为55.8%、41.8%和2.4%,与基线有显著差异(P<0.01)。治疗期间发现轻微扁平隆起和红斑,其中约65%为腺瘤。
长期使用舒林酸似乎对降低FAP患者残留大肠腺瘤的发育异常分级和管状绒毛状腺瘤有效。轻微扁平隆起和红斑可能是腺瘤消退过程中出现的病变。